- In May 2024, Dr. Falk Pharma GmbH, a global leader in hepatology, announced the initiation of a new clinical trial assessing the long-term benefits of ursodeoxycholic acid in combination with novel agents for patients with primary biliary cholangitis (PBC). This study aims to expand therapeutic protocols and improve quality of life for patients with chronic liver conditions. The development reflects Dr. Falk’s ongoing commitment to advancing evidence-based care in hepatobiliary medicine
- In April 2024, Zydus Lifesciences Ltd., a major Indian pharmaceutical company, received approval from the U.S. FDA for its generic version of ursodeoxycholic acid tablets, expanding its presence in the U.S. generics market. This milestone not only enhances access to affordable liver disease treatments but also strengthens Zydus’s footprint in regulated markets with a focus on essential therapeutic areas
- In February 2024, Mitsubishi Tanabe Pharma Corporation announced positive real-world data from a post-marketing surveillance study in Japan on the efficacy and tolerability of UDCA in treating intrahepatic cholestasis. The study supports UDCA’s continued relevance in managing complex liver diseases and reinforces the brand’s trust among healthcare providers
- In January 2024, Sanofi S.A. launched a liver health awareness campaign across select European countries, emphasizing early diagnosis and the benefits of ursodeoxycholic acid in managing bile acid disorders. The campaign aims to improve public knowledge, encourage regular liver function screenings, and boost treatment adherence, especially among aging populations at higher risk for chronic liver diseases
- In December 2023, Apotex Inc., a Canadian pharmaceutical company, entered a distribution agreement to expand the availability of its UDCA formulations in Latin America. The collaboration supports Apotex’s strategy of reaching underserved markets with cost-effective, high-quality generics and addresses the rising burden of liver diseases in the region through improved accessibility to essential medications
